Do analysts prefer PAHC or NNNN?

Phibro Animal Health presently has a consensus target price of $38.80, indicating a potential upside of 19.64%. Given Phibro Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Phibro Animal Health is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, PAHC or NNNN?

Phibro Animal Health has higher revenue and earnings than Anbio Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phibro Animal Health $1.30B 1.01 $48.26M $2.33 13.92 Anbio Biotechnology $8.65M 382.43 $6.40M N/A N/A

Does the media refer more to PAHC or NNNN?

In the previous week, Phibro Animal Health had 3 more articles in the media than Anbio Biotechnology. MarketBeat recorded 4 mentions for Phibro Animal Health and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.11 beat Phibro Animal Health's score of 0.69 indicating that Anbio Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anbio Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LEGN or PAHC?

In the previous week, Legend Biotech had 11 more articles in the media than Phibro Animal Health. MarketBeat recorded 15 mentions for Legend Biotech and 4 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.69 beat Legend Biotech's score of 0.56 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 6 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EWTX or PAHC?

In the previous week, Edgewise Therapeutics had 9 more articles in the media than Phibro Animal Health. MarketBeat recorded 13 mentions for Edgewise Therapeutics and 4 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.69 beat Edgewise Therapeutics' score of 0.04 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phibro Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, PAHC or MANE?

Phibro Animal Health has higher revenue and earnings than Veradermics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phibro Animal Health $1.30B 1.01 $48.26M $2.33 13.92 Veradermics N/A N/A N/A N/A N/A

Does the media refer more to PAHC or MANE?

In the previous week, Veradermics had 2 more articles in the media than Phibro Animal Health. MarketBeat recorded 6 mentions for Veradermics and 4 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.69 beat Veradermics' score of 0.14 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Phibro Animal Health (PAHC) Competitors

$32.43 -0.61 (-1.85%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$32.39 -0.04 (-0.14%)

As of 06/5/2026 07:58 PM Eastern

Compare

PAHC vs. NNNN, LEGN, INDV, EWTX, and MANE

Should you buy Phibro Animal Health stock or one of its competitors? MarketBeat compares Phibro Animal Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Phibro Animal Health include Anbio Biotechnology (NNNN), Legend Biotech (LEGN), Indivior (INDV), Edgewise Therapeutics (EWTX), and Veradermics (MANE). These companies are all part of the "pharmaceutical products" industry.

How does Phibro Animal Health compare to Anbio Biotechnology?

Phibro Animal Health (NASDAQ:PAHC) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Phibro Animal Health has a net margin of 6.35% compared to Anbio Biotechnology's net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Anbio Biotechnology	N/A	N/A	N/A

Phibro Animal Health has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.38, meaning that its share price is 338% more volatile than the broader market.

Phibro Animal Health presently has a consensus target price of $38.80, indicating a potential upside of 19.64%. Given Phibro Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Phibro Animal Health is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phibro Animal Health has higher revenue and earnings than Anbio Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.30B	1.01	$48.26M	$2.33	13.92
Anbio Biotechnology	$8.65M	382.43	$6.40M	N/A	N/A

In the previous week, Phibro Animal Health had 3 more articles in the media than Anbio Biotechnology. MarketBeat recorded 4 mentions for Phibro Animal Health and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.11 beat Phibro Animal Health's score of 0.69 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anbio Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.3% of Phibro Animal Health shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Phibro Animal Health beats Anbio Biotechnology on 11 of the 14 factors compared between the two stocks.

How does Phibro Animal Health compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Legend Biotech presently has a consensus price target of $60.23, indicating a potential upside of 84.64%. Phibro Animal Health has a consensus price target of $38.80, indicating a potential upside of 19.64%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Phibro Animal Health has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.89	-$296.80M	-$0.68	N/A
Phibro Animal Health	$1.30B	1.01	$48.26M	$2.33	13.92

Phibro Animal Health has a net margin of 6.35% compared to Legend Biotech's net margin of -21.98%. Phibro Animal Health's return on equity of 37.14% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Phibro Animal Health	6.35%	37.14%	8.57%

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Legend Biotech had 11 more articles in the media than Phibro Animal Health. MarketBeat recorded 15 mentions for Legend Biotech and 4 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.69 beat Legend Biotech's score of 0.56 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	6 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Legend Biotech has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Summary

Phibro Animal Health beats Legend Biotech on 11 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Indivior?

Indivior (NASDAQ:INDV) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

60.3% of Indivior shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Indivior has a net margin of 19.44% compared to Phibro Animal Health's net margin of 6.35%. Phibro Animal Health's return on equity of 37.14% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Phibro Animal Health	6.35%	37.14%	8.57%

Indivior has higher earnings, but lower revenue than Phibro Animal Health. Phibro Animal Health is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.70	$210M	$1.95	19.29
Phibro Animal Health	$1.30B	1.01	$48.26M	$2.33	13.92

In the previous week, Phibro Animal Health had 4 more articles in the media than Indivior. MarketBeat recorded 4 mentions for Phibro Animal Health and 0 mentions for Indivior. Phibro Animal Health's average media sentiment score of 0.69 beat Indivior's score of 0.53 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Indivior	Positive
Phibro Animal Health	Positive

Indivior has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Indivior currently has a consensus target price of $39.33, suggesting a potential upside of 4.55%. Phibro Animal Health has a consensus target price of $38.80, suggesting a potential upside of 19.64%. Given Phibro Animal Health's higher probable upside, analysts clearly believe Phibro Animal Health is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Indivior beats Phibro Animal Health on 9 of the 17 factors compared between the two stocks.

How does Phibro Animal Health compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Phibro Animal Health has a net margin of 6.35% compared to Edgewise Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Phibro Animal Health	6.35%	37.14%	8.57%

Phibro Animal Health has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Phibro Animal Health	$1.30B	1.01	$48.26M	$2.33	13.92

99.3% of Phibro Animal Health shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Edgewise Therapeutics presently has a consensus price target of $44.22, suggesting a potential upside of 24.25%. Phibro Animal Health has a consensus price target of $38.80, suggesting a potential upside of 19.64%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Edgewise Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Edgewise Therapeutics had 9 more articles in the media than Phibro Animal Health. MarketBeat recorded 13 mentions for Edgewise Therapeutics and 4 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.69 beat Edgewise Therapeutics' score of 0.04 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phibro Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Summary

Phibro Animal Health beats Edgewise Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Phibro Animal Health compare to Veradermics?

Phibro Animal Health (NASDAQ:PAHC) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Phibro Animal Health presently has a consensus price target of $38.80, indicating a potential upside of 19.64%. Veradermics has a consensus price target of $109.00, indicating a potential upside of 18.49%. Given Phibro Animal Health's higher probable upside, research analysts clearly believe Phibro Animal Health is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Veradermics had 2 more articles in the media than Phibro Animal Health. MarketBeat recorded 6 mentions for Veradermics and 4 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 0.69 beat Veradermics' score of 0.14 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Phibro Animal Health has higher revenue and earnings than Veradermics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.30B	1.01	$48.26M	$2.33	13.92
Veradermics	N/A	N/A	N/A	N/A	N/A

Phibro Animal Health has a net margin of 6.35% compared to Veradermics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Veradermics	N/A	N/A	N/A

Summary

Phibro Animal Health beats Veradermics on 8 of the 11 factors compared between the two stocks.

Get Phibro Animal Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAHC vs. The Competition

Export

Metric	Phibro Animal Health	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.32B	$8.48B	$6.68B	$11.99B
Dividend Yield	1.48%	2.52%	2.67%	5.55%
P/E Ratio	13.92	16.14	24.06	23.63
Price / Sales	1.01	6.93	516.28	112.17
Price / Cash	9.92	17.18	42.23	54.60
Price / Book	4.60	3.56	9.73	6.35
Net Income	$48.26M	$224.05M	$3.57B	$337.59M
7 Day Performance	5.33%	-2.11%	-1.28%	-2.52%
1 Month Performance	-24.86%	1.23%	1.38%	-0.03%
1 Year Performance	34.68%	-3.59%	23.93%	25.34%

Phibro Animal Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PAHC Phibro Animal Health	4.7366 of 5 stars	$32.43 -1.8%	$38.80 +19.6%	+34.7%	$1.32B	$1.30B	13.92	2,475
NNNN Anbio Biotechnology	0.8135 of 5 stars	$32.52 +7.8%	N/A	N/A	$4.95B	$8.65M	N/A	27	Positive News
LEGN Legend Biotech	4.095 of 5 stars	$36.16 +41.7%	$59.15 +63.6%	-6.8%	$4.74B	$1.14B	N/A	2,965	Analyst Forecast
INDV Indivior	1.8863 of 5 stars	$33.57 -3.7%	$39.33 +17.2%	+167.4%	$4.39B	$1.24B	17.46	1,051
EWTX Edgewise Therapeutics	2.8194 of 5 stars	$37.20 -7.6%	$44.22 +18.9%	+133.5%	$4.33B	N/A	N/A	60	News Coverage Analyst Forecast Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAHC) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phibro Animal Health (PAHC) Competitors

PAHC vs. NNNN, LEGN, INDV, EWTX, and MANE

How does Phibro Animal Health compare to Anbio Biotechnology?

Summary

How does Phibro Animal Health compare to Legend Biotech?

Summary

How does Phibro Animal Health compare to Indivior?

Summary

How does Phibro Animal Health compare to Edgewise Therapeutics?

Summary

How does Phibro Animal Health compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phibro Animal Health (PAHC) Competitors

PAHC vs. NNNN, LEGN, INDV, EWTX, and MANE

How does Phibro Animal Health compare to Anbio Biotechnology?

Is PAHC or NNNN more profitable?

Which has more volatility and risk, PAHC or NNNN?

Do analysts prefer PAHC or NNNN?

Which has higher earnings and valuation, PAHC or NNNN?

Does the media refer more to PAHC or NNNN?

Do institutionals and insiders believe in PAHC or NNNN?

Summary

How does Phibro Animal Health compare to Legend Biotech?

Do analysts recommend LEGN or PAHC?

Which has preferable valuation & earnings, LEGN or PAHC?

Is LEGN or PAHC more profitable?

Do institutionals & insiders believe in LEGN or PAHC?

Does the media refer more to LEGN or PAHC?

Which has more volatility and risk, LEGN or PAHC?

Summary

How does Phibro Animal Health compare to Indivior?

Do institutionals and insiders hold more shares of INDV or PAHC?

Is INDV or PAHC more profitable?

Which has preferable earnings & valuation, INDV or PAHC?

Does the media favor INDV or PAHC?

Which has more risk and volatility, INDV or PAHC?

Do analysts rate INDV or PAHC?

Summary

How does Phibro Animal Health compare to Edgewise Therapeutics?

Is EWTX or PAHC more profitable?

Which has stronger valuation & earnings, EWTX or PAHC?

Do institutionals & insiders hold more shares of EWTX or PAHC?

Do analysts rate EWTX or PAHC?

Does the media refer more to EWTX or PAHC?

Which has more risk & volatility, EWTX or PAHC?

Summary

How does Phibro Animal Health compare to Veradermics?

Do analysts rate PAHC or MANE?

Does the media refer more to PAHC or MANE?

Do institutionals and insiders hold more shares of PAHC or MANE?

Which has better earnings and valuation, PAHC or MANE?

Is PAHC or MANE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAHC vs. The Competition

Phibro Animal Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools